Stifel raised the firm’s price target on ResMed (RMD) to $270 from $240 and keeps a Hold rating on the shares after what the firm calls “a solid quarter.” Resmed is executing and outgrowing the market, but the firm’s core concern remains its belief that GLP-1 uptake may weigh on future mask and/or device growth, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed price target raised to $270 from $248 at Piper Sandler
- ResMed price target raised to $305 from $283 at Baird
- ResMed price target raised to $325 from $285 at UBS
- Resmed’s Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
- ResMed price target raised to $298 from $274 at KeyBanc